Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Open original sourceLoading market dashboard
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Open original source